Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 2/20 | 0.59 |
| ▸ | CYP46A1 | Q9Y6A2 | 2/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.58 |
| ▸ | OSBP | P22059 | 1/20 | 0.58 |
| ▸ | RORC | P51449 | 1/20 | 0.58 |
| ▸ | OSBP2 | Q969R2 | 1/20 | 0.58 |
| ▸ | POLA1 | P09884 | 1/20 | 0.58 |
| ▸ | GRIN1 | Q05586 | 14/20 | 0.56 |
| ▸ | GRIN2B | Q13224 | 14/20 | 0.56 |
| ▸ | GRIN2A | Q12879 | 12/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27318 | 0.89 | CYP46A1 (0.56) | USP2CYP46A1LMNAABCB1OSBP | |
| SCHEMBL10929500 | 0.88 | USP2 (0.65) | USP2CYP46A1LMNAABCB1OSBP | |
| SCHEMBL10929495 | 0.88 | USP2 (0.65) | USP2CYP46A1LMNAABCB1OSBP | |
| SCHEMBL10930823 | 0.88 | USP2 (0.65) | USP2CYP46A1LMNAABCB1OSBP | |
| SCHEMBL7741660 | 0.85 | USP2 (0.70) | USP2CYP46A1LMNAABCB1OSBP | |
| SCHEMBL4284415 | 0.84 | USP2 (0.69) | USP2CYP46A1LMNAABCB1OSBP | |
| SCHEMBL18310374 | 0.84 | POLA1 (0.70) | USP2CYP46A1LMNAABCB1OSBP | |
| SCHEMBL4624683 | 0.84 | POLA1 (0.70) | USP2CYP46A1LMNAABCB1OSBP | |
| SCHEMBL126915 | 0.84 | POLA1 (0.70) | USP2CYP46A1LMNAABCB1OSBP | |
| SCHEMBL1667802 | 0.84 | POLA1 (0.70) | USP2CYP46A1LMNAABCB1OSBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1602354-B1 | Use of polyglutamic acid or its salts | MEIJI SEIKA KAISHA (JP) | 2008-11-05 | — | — | EP | disclosed |
| US-20060165636-A1 | Hair treatment composition and hair cosmetic for damaged hair | MEIJI SEIKA KAISHA, LTD. (JP) | 2006-07-27 | — | — | US | disclosed |
| EP-1602354-A1 | HAIR TREATMENT COMPOSITION AND HAIR COSMETIC FOR DAMAGED HAIR | Meiji Seika Kaisha, Ltd. (JP) | 2005-12-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060165636-A1 | Hair treatment composition and hair cosmetic for damaged hair | CUTA, COL14A1, PRKDC | USP2 3069/4885CYP46A1 3388/4885LMNA 2112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.